Rachel Woodford

12PUBLICATIONS
80CO-AUTHORS
Molecular targetsPredictive and prognostic markersHaematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Jul 10, 2026
Enhancing Outcome Measurement in Oncology Clinical Trials Through Artificial Intelligence: A Scoping Review.

|Jul 06, 2026
Time to Treatment Failure as an End Point in Pragmatic Oncology Trials: Association With Progression-Free Survival Across Randomized Studies.

|Apr 09, 2026
HosTIL territory: mapping the landscape of toxicity in TIL therapy.

Rachel Woodford, Maria Jose Demiguelarroyo, Ragini Jethra

|Feb 18, 2026
Time to achieve response and depth of maximal tumor response as potential surrogates for overall survival in advanced non-small cell lung cancer.

Rachel Woodford, Sally Lord, Tom John

|Apr 16, 2025
Safety and Activity of Fibroblast Growth Factor Receptor Inhibitors in Advanced Malignancies: A Pooled Analysis of Early-Phase Clinical Trials.

Rafael Grochot, Kroopa Joshi, Antonella Cammarota

|Jan 11, 2024
Validity and Efficiency of Progression-Free Survival-2 as a Surrogate End Point for Overall Survival in Advanced Cancer Randomized Trials.

Rachel Woodford, Deborah Zhou, Peey-Sei Kok

Pageof 2

Frequent Collaborators

4 joint publications

Michael Friedlander

4 joint publications

Ian Marschner

4 joint publications

R John Simes

3 joint publications

Deborah Zhou